Observational studyBritish journal of haematology2026
End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.
Observational study in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.British journal of haematology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While end-of-treatment (EOT) imaging after front-line therapy is prognostic in nodal peripheral T-cell lymphoma (PTCL), its subtype-specific significance remains unclear. Retrospective review of patients with nodal PTCL included in the Australasian Lymphoma and Related Diseases Registry and the Princess Margaret Cancer Centre lymphoma database between 2011 and 2024. Progression-free survival (PFS), overall survival (OS), and positive and negative predictive values (PPV/NPV) of an EOT positron emission tomography/computed tomography response were evaluated. We identified 451 patients. Median follow-up was 43.1-months (95% confidence interval [CI] 38.8%-48.3%). Patients achieving an EOT imaging complete remission (CR) had a 36-month PFS of 43.1% (95% CI 34.3%-51.5%). The 36-month OS was significantly higher in patients achieving CR compared with those who did not achieve a CR (73.5% [95% CI 65.3%-80%] vs. 20.9% [95% CI 12.9%-30.2%]; p < 0.001). EOT imaging CR remained prognostic for OS in all nodal PTCL subtypes (p < 0.001). At 36-months, EOT PET demonstrated a PPV of 90% (95% CI 80.5%-96.2%) and a NPV of 43.1% (95% CI 34.3%-51.5%). EOT PET/CT CR is strongly prognostic of OS across nodal PTCL subtypes with a high PPV for predicting death but poor NPV for predicting survival. Outcomes remain poor for patients not achieving a CR, with suboptimal outcomes even in those achieving CR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.